Back to top
more

Agios Pharmaceuticals (AGIO)

(Delayed Data from NSDQ)

$29.86 USD

29.86
183,729

+0.33 (1.10%)

Updated Apr 22, 2024 11:56 AM ET

After-Market: $30.22 +0.37 (1.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.53% and 4.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Q1 Earnings and Revenues Top Estimates

Baxter (BAX) delivered earnings and revenue surprises of 22.92% and 1.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss

Agios (AGIO) reports mixed fourth-quarter results as earnings beat estimates and revenues miss the same.

Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 142.14% and 2.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day

Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.

Kinjel Shah headshot

Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More

Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.

Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?

Here is how Agios Pharmaceuticals (AGIO) and Alaunos (TCRT) have performed compared to their sector so far this year.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Lags Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.86% and 29.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Down 8.2% Since Last Earnings Report: Can It Rebound?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat

Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.62% and 64.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for March 1st

AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022

Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil

Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -5.85% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More

Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.

Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat

Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.

Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.